11 results about "Intracellular Fluid" patented technology

Proposed is an automated formulation design system and method thereof for determining tablet and capsulation formulations providing a targeted delivery of active pharmaceutical ingredients to a patient with a desired release profile in defined body fluids based on experimental measurements of material attributes for simulated dissolution, disintegration, diffusion, compression, deformation and / or other properties of individual materials or combinations and mixtures thereof. The formulation at least comprises required quantities of the required active pharmaceutical ingredients and excipients providing targeted dissolution and / or solubility factors and / or targeted protection of the active pharmaceutical ingredients during their transport and distribution into interstitial and intracellular fluids.

The invention relates to a structural domain for promoting protein liquid-liquid phase separation, recombinant protein and application of the structural domain. Specifically, the invention relates to a structural domain for promoting protein liquid-liquid phase separation, a nucleic acid molecule, a recombinant protein, a polynucleotide for coding the recombinant protein, a recombinant expression vector, a transformant and applications thereof. The structural domain can enable disordered protein to be subjected to dynamic reversible phase separation under an adversity condition. The method has a good application prospect in promotion of intracellular liquid-liquid phase separation and enrichment.

The application discloses a two-compartment modeling and prediction method for sodium kinetics in hemodialysis. The method divides the patient's body fluid into two compartments of extracellular fluid and intracellular fluid, and establishes a coupled differential equation set to describe the sodium transfer kinetics in the dialysis process. The application corrects the physical error of the existing model in the dispersion equilibrium concentration formula, proposes C_eq=[Na]d / σ (σ=0.97 is the Gibbs-Donnan factor) to replace the traditional Donnan formula and the old recommended formula, eliminates the false dispersion gradient under the condition of isonatric dialysis based on the physical fact that electrolytes are only distributed in the plasma water phase, and removes the error solvent drag term by clearly defining the biophysical constraints of the cell membrane aquaporin not transporting sodium. The application adopts a perturbation reference model to replace the traditional Fick diffusion law to describe the cell membrane sodium exchange, and more accurately reflects the intracellular and extracellular sodium kinetics. The model can accurately predict the serum sodium change and sodium removal under different dialysis prescriptions, and can generate a sodium removal contour map for clinical prescription optimization.

The invention provides a multi-primer designed AAV vector ITR sequence integrity determination method, and belongs to the technical field of next-generation sequencing data analysis and application, and the method comprises the following steps: designing an AAV vector infection host cell with n primers in an ITR region, extracting intracellular fluid, and carrying out next-generation sequencing to obtain a primary Fastq file; the method comprises the following steps: carrying out coarse classification on sequences according to primer information, screening by using a biological information method to obtain a chimeric sequence, aligning one part of the chimeric sequence to a host genome, aligning the other part of the chimeric sequence to an AAV vector genome, and determining the junction of two sequences with different sources in the chimeric sequence as an ITR breakpoint; according to the samples, the primers and the sequence information corresponding to the ITR breakpoints, the distribution condition of the ITR breakpoints in the ITR area is counted, and a statistical table is obtained; and a qualitative and quantitative result of the ITR fracture position is obtained. According to the method, the integrity of the ITR region of the AAV vector sequence can be accurately qualitative and quantitative.

The invention discloses a crystalloid cardioplegia solution, which contains the following proportioning raw materials in every 1000mL crystalloid cardioplegia solution: 6-18g of mannitol, 3.75-11.25g of magnesium sulfate, 2.5-7.5g of sodium bicarbonate, 3.2-9.6g of potassium chloride, 0.24-0.72g of lidocaine, 4.5-13.5g of sodium chloride, 1.25-3.75g of glucose, 6-18 units of insulin, and the remainder is water. The crystalloid cardioplegia solution of the present invention can be used as an intracellular liquid liquid to form an extracellular fluid type blood-containing cardioplegia solution with blood for clinical use, and is flexible in method; the blood after perfusion can directly enter the blood without causing electrolyte imbalance and blood loss; it can be used for antegrade perfusion of the heart, or retrograde perfusion; myocardial edema can be reduced; it has little effect on blood dilution, and a single perfusion can provide a safe arrest time of> 40 minutes; it is convenient to store without a cold chain. The solution of the present invention has superior performance that is unmatched by commercially available cardioplegia solutions in the market.

The invention discloses a sarcopenia assessment system and medical equipment, and the system comprises a data processing module which is used for splitting and preprocessing clinical data; the feature screening module is used for determining an optimal feature subset; the model building and training module is used for building and optimizing a sarcopenia evaluation model; the model evaluation module is used for evaluating the generalization performance of the model; and the practical application module is used for evaluating a new patient. Based on a bioelectrical impedance analysis technology, four key characteristics of gender, body weight, extracellular fluid resistance and intracellular fluid resistance are automatically screened out, and a multi-model preferential strategy is adopted to construct a high-performance evaluation model. According to the method, the defects that a traditional method depends on expensive equipment, complicated processes, subjective indexes and the like are overcome, rapid, objective and accurate screening of sarcopenia is achieved, and an efficient and reliable auxiliary diagnosis tool is provided for clinic.

This application provides a flexible hollow electrostimulation electrode array device and its preparation method, belonging to the field of medical device technology. Specifically, it includes a flexible substrate and a microneedle array; the microneedle array includes multiple microneedles, at least some of which have different heights; the leads of the microneedles are used for electrical connection to a detection device and an electrical pulse generator. When it is necessary to use electroporation to allow macromolecular drugs to enter the intracellular fluid, the flexible hollow electrostimulation electrode array device is implanted into human tissue. Microneedles of different heights penetrate into different depths within the tissue. The leads of the microneedles are first connected to a detection device to detect the neurophysiological signals of the target brain region to determine the location and type of the disease. Then, an electrical pulse generator is connected to provide pulsed current to the microneedles, enabling macromolecular drugs to enter the intracellular fluid through the nanopores of the cell membrane via electroporation for treatment of the lesion. After a period of treatment, the detection device is connected again to assess the treatment effect.

The present disclosure relates to a domain that promotes protein liquid-liquid phase separation, a recombinant protein, and its applications. Specifically, the present disclosure relates to a domain that promotes protein liquid-liquid phase separation, a nucleic acid molecule, a recombinant protein, a polynucleotide encoding the recombinant protein, a recombinant expression vector, a transformant, and their applications. This domain can enable disordered proteins to undergo dynamic, reversible phase separation under adverse conditions. It has promising application prospects in promoting intracellular liquid-liquid phase separation and enrichment.

The invention provides a flexible hollow electrical stimulation electrode array device and a preparation method thereof, and belongs to the technical field of medical instruments, and the flexible hollow electrical stimulation electrode array device specifically comprises a flexible substrate and a microneedle array; the microneedle array comprises a plurality of microneedles, and at least parts of the microneedles are different in height; the lead wire end of the microneedle is used for being electrically connected with detection equipment and electric pulse generation equipment. When macromolecular medicine needs to enter intracellular fluid by means of electroporation, the flexible hollow electrical stimulation electrode array device is implanted into human tissue, the microneedles with different heights penetrate into different depths in the tissue, the lead ends of the microneedles are firstly connected with detection equipment, neural electrophysiological signals of a target brain area are detected through the detection equipment, and the detection equipment is used for detecting the intracellular fluid in the target brain area. According to the method, the position and the type of a disease are judged, then electric pulse generation equipment is connected to provide pulse current for the microneedle, so that macromolecular drugs can open nanometer through holes of cell membranes through electroporation to enter intracellular fluid to treat the focus position, and after treatment is conducted for a period of time, detection equipment is connected to judge the treatment effect.

The invention belongs to the technical field of biomedical engineering, and particularly relates to intelligent sign monitoring for a pet anesthesia period and a drying system, which comprises a non-intrusive multi-band biological impedance spectroscopy technology, fusion of vital signs and environmental parameter monitoring, real-time evaluation of pet hydration state and electrolyte balance through a core processing module, and real-time monitoring of pet drying. And the environmental parameters are adaptively regulated and controlled. By means of the biological impedance spectroscopy technology, dynamic changes of extracellular fluid and intracellular fluid in a pet body can be directly perceived, and therefore the dehydration risk is recognized in the early stage before hysteresis changes of traditional vital signs occur; through a self-adaptive regulation and control strategy, rapid dehydration and electrolyte disorder caused by drying or anesthesia are actively prevented, the system has high integration, intelligence and safety, and the physiological safety of small pets in the anesthesia period and the drying process can be remarkably improved.

The invention relates to a non-cryopreserved cell preservation solution and application thereof. The cell preservation solution comprises a basic solution and a core additive, wherein the core additive comprises a ferroptosis inhibitor and a mitochondrial protective agent, based on an intracellular fluid type ionic environment and multi-mechanism synergy, an optimized basic fluid system with high potassium, low sodium and histidine buffering is adopted, the ferroptosis inhibitor and the mitochondrial targeted protective agent are integrated, and by simulating an intracellular environment, stabilizing pH and inhibiting a key death pathway, the activity of the ferroptosis inhibitor is improved; the survival rate and the functional activity of various cells under the low-temperature non-cryopreservation condition are remarkably improved, and the method has important application significance in the field of cell preservation.